Charles Explorer logo
🇬🇧

Long time successful treatment of a young patient suffering from advanced ALK rearreged lung adenocarcinoma

Publication at Faculty of Medicine in Pilsen, Second Faculty of Medicine |
2018

Abstract

Authors present a casereport of young man suffering from ALK-driven lung adenocarcinoma with multiple train metastases. After first time treatment with vinorelbin, cisplatina and bevacizumab.

Metastatic lesions were manged by surgery and Leksells gamma knife. The disease was controlled for three years by second-line given crizotinib.

Intrathoracic tumour progression was treated by radiotherapy, after repeated refuse of ceritinib reimbursement by health company, ceritinib was given to the patient from foreign oncologic specialist for 90 days. Patient is on alectinib therapy since november 2017, brain metastases regressed after LGN irradiation and targeted therapy in nearly complete regression.

Patient is alive and well 8. year after diagnosis of lung cancer of stage IV.